Our technology

Innovative genetic medicines targeting the core drivers of neurodegenerative disease.

Our approach

At Celosia Therapeutics, we focus on the underlying biological causes of neurodegenerative disease. Our work is centred on developing genetic medicines that target the processes driving conditions such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Alzheimer’s disease.

By combining deep neuroscience expertise with innovative genetic approaches, we aim to turn scientific discovery into therapies that can meaningfully change how these diseases progress.

TDP-43 explained

TDP-43 is a protein that plays an essential role in healthy nerve cells and is central to both ALS and FTD. In disease, TDP-43 moves to the wrong part of the cell, where it accumulates, becomes toxic, and damages neurons.

This abnormal behaviour of TDP-43 is a defining feature in the majority of ALS and many FTD cases, making it a compelling and highly relevant therapeutic target.

Our lead gene therapy program

CTx1000 is Celosia Therapeutics’ lead AAV-based gene therapy program designed to address toxic TDP-43 directly.

Using a novel genetic medicine approach, our therapy is designed to reduce harmful TDP-43 inside affected nerve cells, with the goal of slowing or halting neurodegeneration in ALS and FTD. This program targets a core disease mechanism rather than symptoms, with the potential to create durable impact.

The therapy is based on 15+ years of research by Professors Lars Ittner and Yazi Diana Ke at Macquarie University and is owned by Celosia.

Our programs

Celosia have various programs focused on key disease drivers across neurodegenerative conditions.

Clinical Pipeline